RT Journal Article SR Electronic T1 Global quality of life in breast cancer: systematic review and meta-analysis JF BMJ Supportive & Palliative Care JO BMJ Support Palliat Care FD British Medical Journal Publishing Group SP bmjspcare-2022-003642 DO 10.1136/bmjspcare-2022-003642 A1 Akbar Javan Biparva A1 Samira Raoofi A1 Sima Rafiei A1 Fatemeh Pashazadeh Kan A1 Mitra Kazerooni A1 Farzaneh Bagheribayati A1 Maryam Masoumi A1 Maryam Doustmehraban A1 Mohaddeseh Sanaei A1 Farnaz Zarabi A1 Neda Raoofi A1 Zahra Beiramy Chomalu A1 Behrooz Ahmadi A1 Fatemeh Seyghalani Talab A1 Batool Sadat Hoseini A1 Elnaz Asadollahi A1 Maryam Mir A1 Sama Deylami A1 Mahsa Zareei A1 Hadis Sanaei A1 Fateme Dousti nia Kakavand A1 Hooman Koohestani A1 Mahmoud Nasiri A1 Negin Vali A1 Ahmad Ghashghaee YR 2022 UL http://spcare.bmj.com/content/early/2022/08/21/bmjspcare-2022-003642.abstract AB Background Breast cancer (BC) is the most common cancer among women worldwide. We conducted a systematic review and meta-analysis to cover the existing research gap and contribute to existing knowledge to provide both researchers and clinicians with a better profile on the topic and consequently help improve the quality of life (QoL) of patients with BC.Methods A comprehensive review of original articles published in English from January 2000 to October 2021 from databases including Embase, Scopus, PubMed and Web of Science was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.Results Based on the meta-regression which examined a total of 9012 patients with BC, the QoL score calculated by EORTC QLQ-C30 was 64.72 (95% CI 59.24 to 70.20), while the score obtained from FACT-B was 84.39 (95% CI 64.24 to 104.54) and the scores from QLQ-BR23 and SF-36 were 66.33 (95% CI 62.76 to 69.90) and 57.23 (95% CI 47.65 to 66.82), respectively. A meta-analysis affirmed a significant direct relationship between the QoL score of patients with BC and their age (p=0.03). The results also revealed that the QoL scores of patients who had completed treatment were higher than those who were currently under treatment.Conclusion The present systematic review identified several factors that affect the QoL of women with BC worldwide and provided several implications for developing policy interventions to effectively improve the QoL of women with BC. In this way, clinicians can sufficiently give advice to their patients with the purpose of improving their QoL.PROSPERO registration number CRD42022309791.